Literature DB >> 12660544

Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and non-nucleoside inhibitors in a patient failing highly active antiretroviral therapy.

Stefania Paolucci1, Fausto Baldanti, Marco Tinelli, Giovanni Maga, Giuseppe Gerna.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12660544     DOI： 10.1097/00002030-200304110-00022

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  7 in total

Review 1.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

2.  A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.

Authors:  Stefania Paolucci; Fausto Baldanti; Giovanni Maga; Reynel Cancio; Maurizio Zazzi; Maurizio Zavattoni; Antonella Chiesa; Silvio Spadari; Giuseppe Gerna
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Authors:  Soumi Gupta; Signe Fransen; Ellen E Paxinos; Eric Stawiski; Wei Huang; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

5.  Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Atsuko Hachiya; Eiichi N Kodama; Stefan G Sarafianos; Matthew M Schuckmann; Yasuko Sakagami; Masao Matsuoka; Masafumi Takiguchi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.

Authors:  Vici Varghese; Yumi Mitsuya; Rajin Shahriar; Michael H Bachmann; W Jeffrey Fessel; Ron M Kagan; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

7.  N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Authors:  Soo-Huey Yap; Chih-Wei Sheen; Jonathan Fahey; Mark Zanin; David Tyssen; Viviane Dias Lima; Brian Wynhoven; Michael Kuiper; Nicolas Sluis-Cremer; P Richard Harrigan; Gilda Tachedjian
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.